Contineum Therapeutics, Inc.
contineum-tx.comWhat Do They Do?
Develops small-molecule drug candidates for people with idiopathic pulmonary fibrosis and chronic pain, and licenses a candidate for depression and multiple sclerosis to Johnson & Johnson.
10-K for FY2025, filed Mar 5, 2026Our wholly-owned lead asset, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor…View ↗
Our second novel drug candidate, PIPE-307, is a selective, small-molecule inhibitor of the muscarinic type 1 receptor (“M1R”), in…View ↗
We have a portfolio of novel and proprietary small molecule programs that we believe can modulate innate pathways to restore function in…View ↗
Who Are Their Customers?
Johnson & Johnson is the licensee for PIPE-307, with worldwide rights to develop, manufacture and commercialize it.
10-K for FY2025, filed Mar 5, 2026In February 2023, we entered into a license agreement with J&J (the “J&J License Agreement”), pursuant to which we granted J&J an…View ↗
How Are They Changing?
-
Sep 14, 2026
MOONLIGHT-1 depression trial misses its primary efficacy endpoint
The MOONLIGHT-1 Phase 2 trial did not meet its primary efficacy endpoint; analyses of exploratory endpoints continued.
Sources
8-K, filed Sep 14, 2026
–Phase 2 MOONLIGHT-1 trial did not meet its primary efficacy endpointView ↗
Who Do They Compete With?
Competes with Genentech/Roche, Boehringer Ingelheim, and Bristol Myers Squibb
10-K for FY2025, filed Mar 5, 2026While there is no pharmacological cure for IPF, there are three FDA-approved therapies to treat the disease: pirfenidone (Esbriet, marketed…View ↗
Loading...
